{"id":"NCT03891758","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Confirmatory Study of BK1310 in Healthy Infants","officialTitle":"Phase 3 Study of BK1310 Compared With ActHIB® and Tetrabik in Healthy Infants: A Randomized, Assessor-blind, Active-controlled","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-01","primaryCompletion":"2019-09-18","completion":"2020-08-10","firstPosted":"2019-03-27","resultsPosted":"2025-01-06","lastUpdate":"2025-01-06"},"enrollment":267,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Tetanus","Diphtheria","Pertussis","Poliomyelitis","Bacterial Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"DPT-IPV-Hib","otherNames":["BK1310"]},{"type":"BIOLOGICAL","name":"Hib vaccine","otherNames":["ActHIB®"]},{"type":"BIOLOGICAL","name":"DPT-IPV","otherNames":["Tetrabik"]}],"arms":[{"label":"BK1310","type":"EXPERIMENTAL"},{"label":"ActHIB® and Tetrabik","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with co-administration of ActHIB® and Tetrabik, as well as efficacy and safety, in healthy infants.","primaryOutcome":{"measure":"Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Anti-PRP","timeFrame":"4 weeks after the primary immunization (Visit 4)","effectByArm":[{"arm":"BK1310","deltaMin":100,"sd":null},{"arm":"ActHIB® and Tetrabik (Control)","deltaMin":88.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["38582691"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":133},"commonTop":["Injection site erythema","Pyrexia","Injection site induration","Injection site swelling","Irritability postvaccinal"]}}